About Seragon Pharmaceuticals
Seragon Pharmaceuticals is a Healthcare company based in San Diego (United States) founded in 2013, and was acquired by Genentech in July 2014. Selective estrogen receptor degraders are developed for breast cancer treatment. Seragon Pharmaceuticals has raised $30 million across 1 funding round from investors including Genentech, Orbimed and The Column Group. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include C4 Therapeutics, Erasca and MiRagen; 3 of its 3 listed competitors have raised funding.
Company details
Seragon Pharmaceuticals was founded in 2013 and is based in San Diego, United States. Operations focus on the biotechnology sector, specifically the development of orally active selective estrogen receptor degraders (SERDs) for estrogen receptor-dependent breast cancer. These compounds function as antagonists that induce receptor degradation, with multiple candidates identified for their pharmacokinetic profiles supporting anti-tumor activity.
- Headquarters San Diego, United States
- Stage Acquired
- SectorsHealthcare
- Website seragonpharm.com
- Acquired by Genentech (Jul 2014)
Funding Insights of Seragon Pharmaceuticals
Seragon Pharmaceuticals has successfully raised a total of $30M through 1 strategic funding round. The most recent funding activity was a Series A round of $30 million completed in October 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $30M
- Total Rounds 1
- Last Round Series A — $30M
- First Round $30M
(Oct 2013)
- Investors Count 5
All 1 funding rounds of Seragon Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2013 | $30M | Series A | – | – |
6 investors in total: 6 institutional.
Investors in Seragon Pharmaceuticals
Seragon Pharmaceuticals has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Genentech, Orbimed and The Column Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A life sciences investment firm focused on novel therapeutics is operated. | 2011 | venbio.com | San Francisco, United States | |
Biotech sectors are targeted for investments by Topspin Fund. | topspinfund.com | Roslyn Heights, United States | ||
PE firm investing in the US | aislingcapital.com | New York, United States | ||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Early-stage investments in US life science startups are focused on. | 2007 | thecolumngroup.com | San Francisco, United States | |
R&D company focused on manufacturing drugs for multiple therapeutic areas | 1976 | gene.com | San Francisco, United States |
Investor details for Seragon Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Seragon Pharmaceuticals
3 dated milestones of Seragon Pharmaceuticals across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Seragon Pharmaceuticals is founded.
- Funding First funding round of $30.0M.
- Exit Acquired by Genentech.
Competitors of Seragon Pharmaceuticals
Seragon Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and MiRagen.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. |
Detailed competitors of Seragon Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Seragon Pharmaceuticals (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Seragon Pharmaceuticals
Complete news archive for Seragon Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Seragon Pharmaceuticals
Seragon Pharmaceuticals was founded in 2013.
Seragon Pharmaceuticals is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Seragon Pharmaceuticals is a funded company, having raised a total of $30M across 1 funding round to date. The company's 1st funding round was a Series A of $30M, raised on Oct 2013.
Seragon Pharmaceuticals was founded in 2013 and is based in San Diego, United States. Operations focus on the biotechnology sector, specifically the development of orally active selective estrogen receptor degraders (SERDs) for estrogen receptor-dependent breast cancer. These compounds function as antagonists that induce receptor degradation, with multiple candidates identified for their pharmacokinetic profiles supporting anti-tumor activity.
Seragon Pharmaceuticals's top competitors include C4 Therapeutics, Erasca and MiRagen.
Seragon Pharmaceuticals has 6 investors. Key investors include Genentech, Orbimed, The Column Group, venBio, and Topspin Fund.
Yes. Seragon Pharmaceuticals was acquired by Genentech in July 2014.